Now showing items 1-3 of 3

    • Hypothalamic mTOR Signaling Mediates the Orexigenic Action of Ghrelin 

      Martins, Luis; Fernández-Mayo, Diana; Novelle, Marta G.; Vázquez, María J.; Nogeiras, Rubén; López, Miguel; Diéguez, Carlos; Tena-Sempere, Manuel (Public Library Of Science (PLOS), 2012)
      Current evidence suggests that ghrelin, a stomach derived peptide, exerts its orexigenic action through specific modulation of Sirtuin1 (SIRT1)/p53 and AMP-activated protein kinase (AMPK) pathways, which ultimately increase ...
    • mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence 

      Guerrero, Marta; Ferrín, Gustavo; Rodríguez-Perálvarez, Manuel; González Rubio, Sandra; Sánchez-Frías, Marina; Amado, Víctor; Pozo, Juan C.; Poyato, Antonio; Ciria, Rubén; Ayllón Terán, M. Dolores; Barrera, Pilar; Montero, José L.; Mata, Manuel de la (MDPI, 2019)
      (1) Background: The mammalian target of rapamycin (mTOR) pathway activation is critical for hepatocellular carcinoma (HCC) progression. We aimed to evaluate the mTOR tissue expresión in liver transplant (LT) patients and ...
    • Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor 

      Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Battelli, Nicola; Montironi, Rodolfo; Massari, Francesco (MDPI, 2019)
      The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with ...